133 related articles for article (PubMed ID: 37257835)
1. Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor.
le Sève JD; Guédon AF; Bordenave S; Agard C; Connault J; Pistorius MA; Quéreux G; Espitia O
Thromb Haemost; 2023 Nov; 123(11):1049-1056. PubMed ID: 37257835
[TBL] [Abstract][Full Text] [Related]
2. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
3. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
Moik F; Chan WE; Wiedemann S; Hoeller C; Tuchmann F; Aretin MB; Fuereder T; Zöchbauer-Müller S; Preusser M; Pabinger I; Ay C
Blood; 2021 Mar; 137(12):1669-1678. PubMed ID: 33067632
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
[TBL] [Abstract][Full Text] [Related]
6. Interaction between NSCLC Cells, CD8
Freitas-Dias C; Gonçalves F; Martins F; Lemos I; Gonçalves LG; Serpa J
Cells; 2024 Feb; 13(4):. PubMed ID: 38391918
[TBL] [Abstract][Full Text] [Related]
7. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
8. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
10. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy.
Hill H; Robinson M; Lu L; Slaughter D; Amin A; Mileham K; Patel JN
Thromb Res; 2021 Dec; 208():71-78. PubMed ID: 34742139
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and Outcomes of Cancer Patients With Venous Thromboembolic Events After Treatment With Immune Checkpoint Inhibitors.
Dutra B; Garcia-Rodriguez V; Garcia R; Szafron D; Abraham F; Khurana S; Lockhart J; Amin R; Wang Y; Thomas A
Am J Clin Oncol; 2023 Mar; 46(3):94-100. PubMed ID: 36735530
[TBL] [Abstract][Full Text] [Related]
13. Association between immune-related adverse events and prognosis in patients treated with immune checkpoint inhibitors in melanoma: A surrogacy analysis.
Euvrard R; Robert M; Mainbourg S; Dalle S; Lega JC
Fundam Clin Pharmacol; 2024 Apr; 38(2):369-379. PubMed ID: 38012082
[TBL] [Abstract][Full Text] [Related]
14. Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer.
Sumi T; Sekikawa M; Nagahisa Y; Matsuura K; Shijubou N; Kamada K; Watanabe H; Yamada Y; Tanaka Y; Chiba H
Invest New Drugs; 2022 Dec; 40(6):1315-1321. PubMed ID: 36269521
[TBL] [Abstract][Full Text] [Related]
15. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
17. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
18. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
Icht O; Darzi N; Shimony S; Jacobi O; Reinhorn D; Landman Y; Mutai R; Averbuch I; Shochat T; Spectre G; Raanani P; Rotem O; Dudnik E; Peled N; Zer A; Leader A
J Thromb Haemost; 2021 May; 19(5):1250-1258. PubMed ID: 33605020
[TBL] [Abstract][Full Text] [Related]
19. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
[TBL] [Abstract][Full Text] [Related]
20. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study.
Kobayashi T; Iwama S; Yasuda Y; Okada N; Okuji T; Ito M; Onoue T; Goto M; Sugiyama M; Tsunekawa T; Takagi H; Hagiwara D; Ito Y; Suga H; Banno R; Yokota K; Hase T; Morise M; Hashimoto N; Ando M; Fujimoto Y; Hibi H; Sone M; Ando Y; Akiyama M; Hasegawa Y; Arima H
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32606047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
